Shots:

• The approval is based on pivotal phase III ATLAS and FLAIR study assessing Cabenuva in 1-100+ HIV-1 adults to replace the current ARV regimen in those who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen
• Prior to initiating treatment of Cabenuva- oral dosing of cabotegravir and rilpivirine should be administered for ~1mos. to assess the tolerability of each therapy. The therapy reduces the treatment dosing days from 365 days to 12days/ yr
• The company will begin shipping of Cabenuva to wholesalers and specialty distributors in the US in Feb’2021

 ­ Ref: Businesswire | Image: ViiV Healthcare